Search
Displaying 851–860 of 994 results
-
Research News
An advisory committee comprised of FDA-selected experts voted unanimously – 16 to 0 – to recommend approval.
-
Research News
Investigational LUXTURNA has the potential to be both the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the United States
First adeno-associated viral (AAV) vector investigational candidate to reach this stage of FDA review
Investigational LUXTURNA clinical program includes up to four years of efficacy data, with observation ongoing
-
Beacon Stories
Joe Caruso, founder of FOCUS Wine Foundation, knows life both with and without the ability to see. His first memory is sitting in the waiting room with his mother at the Scheie Eye Institute in Philadelphia.
-
The Foundation's Investments Are Filling the Pipeline for Vision-Saving Therapies
Research NewsIn addition to funding promising biotech start-ups, the Foundation Fighting Blindness has played a critical role in developing research talent.
-
Heather Presnar’s Story: Living with Stargardt Disease
Beacon StoriesWhen you’re the catcher, the ball always comes to you. Heather Presnar wouldn’t have had it any other way.
-
MeiraGTx Treats First Patient in XLRP Gene-Therapy Trial
Research NewsThe MeiraGTx gene therapy involves injection of healthy copies of RPGR underneath the retina. The RPGR copies are contained in a human-engineered virus — known as an adeno-associated virus or AAV — designed to readily penetrate retinal cells to deliver the therapeutic genetic cargo.
-
Sight and Song: The Christian Guardino Story
Beacon StoriesChristian Guardino has been singing for as long as he can remember; it’s the seeing that is something new.
-
Scientists Receive $25 Million to Develop a Vision-Restoring System that Connects to the Brain
Research NewsThe high-tech, vision-restoring system interfaces with the visual cortex, the back of the brain where visual input is processed to create the images we see.
-
Research News
The partnership will help companies and researchers quickly obtain and implement high-quality vectors for their retinal gene-therapy development efforts.
-
FFB-Funded Scientists Report on Nine Promising Translational Research Efforts
Research NewsThe Foundation Fighting Blindness has taken the translational challenge head on by investing more than $75 million in therapy-development projects with strong clinical-trial potential through its Translational Research Acceleration Program (TRAP), which includes Gund-Harrington Scholar Awards.
